Chemo Pharma Laboratories Limited has announced the receipt of a significant request from one of its Promoter Group Shareholders. Ms. Shanta Somani has formally sought reclassification from the 'Promoter Group Shareholder' category to the 'Public Shareholder' category, as per the regulations set by the Securities and Exchange Board of India (SEBI).

Request Details

The company disclosed that Ms. Somani submitted her request on August 11, 2025, at 2:57 PM. This move is in accordance with Regulation 31A of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, commonly known as SEBI (LODR) Regulations, 2015.

Next Steps

Chemo Pharma Laboratories has stated that the reclassification request will be taken up for consideration by the company's Board of Directors. The board is expected to discuss this matter in an upcoming meeting, which is yet to be scheduled.

Management Statement

Mr. Ruchit Mehta, Managing Director & Chief Executive Officer of Chemo Pharma Laboratories Limited, confirmed the receipt of the request letter. In the company's communication to the Bombay Stock Exchange, he stated:

"The request letter submitted by Ms. Shanta Somani (Promoter Group Shareholder) will be considered by the Board of Directors of the Company in the ensuing Board Meeting to be scheduled shortly."

Regulatory Compliance

The company has assured stakeholders that it will adhere to all necessary regulatory procedures. An intimation regarding the upcoming Board Meeting will be disclosed by the company in due course, ensuring transparency in the process.

About Chemo Pharma Laboratories Limited

Chemo Pharma Laboratories Limited is a publicly listed company on the Bombay Stock Exchange. The company's registered office is located in Kalyan, Thane district, while its corporate office is situated in Fort, Mumbai.

Investors and market observers will be keenly watching for further developments on this reclassification request, as such changes can potentially impact the company's shareholding structure and market perception. Chemo Pharma Laboratories Limited has committed to providing updates as the process unfolds, maintaining open communication with its shareholders and the public.

Chemo Pharma Laboratories Limited has announced a significant change in its statutory auditor position, marking a transition in the company's financial oversight.

Resignation of Current Auditor

M/s Sanjay Rane & Associates LLP, the company's current statutory auditors, have stepped down from their role. The firm cited pre-occupation with other assignments as the reason for their departure. Their resignation letter, dated July 23, 2025, was formally accepted by the Board of Directors on July 31, 2025.

The Audit Committee, after careful consideration of the resignation, confirmed that the outgoing auditors raised no concerns or issues regarding their departure. The Board expressed its appreciation for M/s Sanjay Rane & Associates LLP's contribution to the company, particularly noting their adherence to high audit processes and standards.

Appointment of New Auditor

In response to this change, the Board of Directors has recommended the appointment of M/s. S S R V & Associates, Chartered Accountants, as the new statutory auditors of Chemo Pharma Laboratories Limited. This appointment, effective from July 29, 2025, is subject to shareholder approval at the upcoming General Meeting.

Profile of New Auditor

M/s. S S R V & Associates brings a strong reputation to their new role:

• The firm holds the Firm Registration Number (FRN) 135901W
• It is a peer-reviewed partnership firm, with peer review certificate number 014729 issued by The Institute of Chartered Accountants of India (ICAI)
• Vishnu Kant Kabra, a partner at S S R V & Associates, brings over 20 years of experience to the table
• Areas of expertise include Direct Taxation, Indirect Taxation, Internal & Statutory Audits, Bank Audits, and Fund Raising for both listed and unlisted companies

Regulatory Compliance

This change in auditors complies with the applicable provisions of the Companies Act 2013 and the SEBI Listing Regulations, 2015. The company has also adhered to the SEBI Circular No. CIR/CFD/CMD1/114/2019 dated October 18, 2019, ensuring transparency in the auditor transition process.

The Board meeting discussing these changes commenced at 10:00 AM and concluded at 10:25 AM on July 31, 2025. Ruchit Mehta, Managing Director & Chief Executive Officer of Chemo Pharma Laboratories Limited, signed off on the official communication to the Bombay Stock Exchange.

This transition in statutory auditors represents a significant corporate governance event for Chemo Pharma Laboratories Limited, potentially bringing fresh perspectives to the company's financial reporting and auditing processes.